≡

Anaplastic Lymphoma Kinase (ALK)

[Edit]

CD246; TFG/ALK; Ki1; Anaplastic Lymphoma Receptor Tyrosine Kinase

Anaplastic Lymphoma Kinase (ALK)
CCC A870
HGNC 427
MGI 103305
PubMed 18097461
UniProt Q9UM73
Wiki ALK

The 2;5 chromosomal translocation is frequently associated with anaplastic large cell lymphomas (ALCLs). The translocation creates a fusion gene consisting of the ALK gene and the nucleophosmin (NPM) gene: the 3' half of ALK, derived from chromosome 2, is fused to the 5' portion of NPM from chromosome 5. The product of the NPM-ALK fusion gene is oncogenic. The deduced amino acid sequences reveal that ALK is a novel receptor tyrosine kinase having a putative transmembrane domain and an extracellular domain. These sequences are absent in the product of the transforming NPM-ALK gene. ALK shows the greatest sequence similarity to LTK (leukocyte tyrosine kinase). ALK plays an important role in the development of the brain and exerts its effects on specific neurons in the nervous system.

Organism species: Homo sapiens (Human)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins RPA870Hu01 Recombinant Anaplastic Lymphoma Kinase (ALK) Positive Control; Immunogen; SDS-PAGE; WB.
Antibodies PAA870Hu01 Polyclonal Antibody to Anaplastic Lymphoma Kinase (ALK) WB; IHC; ICC; IP.
Assay Kits n/a CLIA Kit for Anaplastic Lymphoma Kinase (ALK) CLIA Kit Customized Service Offer
n/a ELISA Kit for Anaplastic Lymphoma Kinase (ALK) ELISA Kit Customized Service Offer

Organism species: Mus musculus (Mouse)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Recombinant Anaplastic Lymphoma Kinase (ALK) Recombinant Protein Customized Service Offer
Antibodies n/a Monoclonal Antibody to Anaplastic Lymphoma Kinase (ALK) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Anaplastic Lymphoma Kinase (ALK) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Anaplastic Lymphoma Kinase (ALK) CLIA Kit Customized Service Offer
n/a ELISA Kit for Anaplastic Lymphoma Kinase (ALK) ELISA Kit Customized Service Offer
  1. "ALK, the chromosome 2 gene locus altered by the t(2;5) in non-Hodgkin's lymphoma, encodes a novel neural receptor tyrosine kinase that is highly related to leukocyte tyrosine kinase (LTK)."Oncogene 14:2175-2188(1997) [PubMed] [Europe PMC] [Abstract]
  2. ErratumOncogene 15:2883-2883(1997)
  3. "Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system."Oncogene 14:439-449(1997) [PubMed] [Europe PMC] [Abstract]
  4. "Generation and annotation of the DNA sequences of human chromosomes 2 and 4." Nature 434:724-731(2005) [PubMed] [Europe PMC] [Abstract]
  5. "Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin's lymphoma."Science 263:1281-1284(1994) [PubMed] [Europe PMC] [Abstract]
  6. "The cytoplasmic truncated receptor tyrosine kinase ALK homodimer immortalizes and cooperates with ras in cellular transformation."FASEB J. 15:1416-1418(2001) [PubMed] [Europe PMC] [Abstract]
  7. "Activation of anaplastic lymphoma kinase receptor tyrosine kinase induces neuronal differentiation through the mitogen-activated protein kinase pathway."J. Biol. Chem. 276:9526-9531(2001) [PubMed] [Europe PMC] [Abstract]
  8. "Identification of anaplastic lymphoma kinase as a receptor for the growth factor pleiotrophin."J. Biol. Chem. 276:16772-16779(2001) [PubMed] [Europe PMC] [Abstract]
  9. "Identification of novel fusion partners of ALK, the anaplastic lymphoma kinase, in anaplastic large-cell lymphoma and inflammatory myofibroblastic tumor."Genes Chromosomes Cancer 34:354-362(2002) [PubMed] [Europe PMC] [Abstract]
  10. "Pleiotrophin signaling through anaplastic lymphoma kinase is rate-limiting for glioblastoma growth."J. Biol. Chem. 277:14153-14158(2002) [PubMed] [Europe PMC] [Abstract]
  11. "Anti-apoptotic signaling of pleiotrophin through its receptor, anaplastic lymphoma kinase."J. Biol. Chem. 277:35862-35868(2002) [PubMed] [Europe PMC] [Abstract]
  12. "Midkine binds to anaplastic lymphoma kinase (ALK) and acts as a growth factor for different cell types."J. Biol. Chem. 277:35990-35998(2002) [PubMed] [Europe PMC] [Abstract]
  13. "ALK receptor tyrosine kinase promotes cell growth and neurite outgrowth."J. Cell Sci. 117:3319-3329(2004) [PubMed] [Europe PMC] [Abstract]
  14. "Unique substrate specificity of anaplastic lymphoma kinase (ALK): development of phosphoacceptor peptides for the assay of ALK activity."Biochemistry 44:8533-8542(2005) [PubMed] [Europe PMC] [Abstract]
  15. "Differential induction of glioblastoma migration and growth by two forms of pleiotrophin."J. Biol. Chem. 280:26953-26964(2005) [PubMed] [Europe PMC] [Abstract]
  16. "Role of the subcellular localization of ALK tyrosine kinase domain in neuronal differentiation of PC12 cells."J. Cell Sci. 118:5811-5823(2005) [PubMed] [Europe PMC] [Abstract]
  17. "Immunoaffinity profiling of tyrosine phosphorylation in cancer cells."Nat. Biotechnol. 23:94-101(2005) [PubMed] [Europe PMC] [Abstract]
  18. "Fusion of the SEC31L1 and ALK genes in an inflammatory myofibroblastic tumor."Int. J. Cancer 118:1181-1186(2006) [PubMed] [Europe PMC] [Abstract]
  19. "ALK activation induces Shc and FRS2 recruitment: Signaling and phenotypic outcomes in PC12 cells differentiation."FEBS Lett. 581:727-734(2007) [PubMed] [Europe PMC] [Abstract]
  20. "Anaplastic lymphoma kinase is activated through the pleiotrophin/receptor protein-tyrosine phosphatase beta/zeta signaling pathway: an alternative mechanism of receptor tyrosine kinase activation."J. Biol. Chem. 282:28683-28690(2007) [PubMed] [Europe PMC] [Abstract]
  21. "Recruitment of insulin receptor substrate-1 and activation of NF-kappaB essential for midkine growth signaling through anaplastic lymphoma kinase."Oncogene 26:859-869(2007) [PubMed] [Europe PMC] [Abstract]
  22. "Anaplastic lymphoma kinase: signalling in development and disease."Biochem. J. 420:345-361(2009) [PubMed] [Europe PMC] [Abstract]
  23. "Solution structure of the complex of the PTB domain of SNT-2 and 19-residue peptide (aa 1571-1589) of HALK."Submitted (APR-2008) to the PDB data bank
  24. "Crystal structure of the ALK (anaplastic lymphoma kinase) catalytic domain."Biochem. J. 430:425-437(2010) [PubMed] [Europe PMC] [Abstract]
  25. "Crystal structures of anaplastic lymphoma kinase in complex with ATP competitive inhibitors."Biochemistry 49:6813-6825(2010) [PubMed] [Europe PMC] [Abstract]
  26. "Structural basis for the recognition of nucleophosmin-anaplastic lymphoma kinase oncoprotein by the phosphotyrosine binding domain of Suc1-associated neurotrophic factor-induced tyrosine-phosphorylated target-2."J. Struct. Funct. Genomics 11:125-141(2010) [PubMed] [Europe PMC] [Abstract]
  27. "Structure of L1196M mutant anaplastic lymphoma kinase in complex with crizotinib."Submitted (MAY-2011) to the PDB data bank
  28. "CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant."Cancer Cell 19:679-690(2011) [PubMed] [Europe PMC] [Abstract]
  29. "Patterns of somatic mutation in human cancer genomes." Nature 446:153-158(2007) [PubMed] [Europe PMC] [Abstract]
  30. "Identification of ALK as a major familial neuroblastoma predisposition gene." Nature 455:930-935(2008) [PubMed] [Europe PMC] [Abstract]
  31. "Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma."Nature 455:967-970(2008) [PubMed] [Europe PMC] [Abstract]
  32. "Activating mutations in ALK provide a therapeutic target in neuroblastoma." Nature 455:975-978(2008) [PubMed] [Europe PMC] [Abstract]
  33. "The constitutive activity of the ALK mutated at positions F1174 or R1275 impairs receptor trafficking."Oncogene 30:2017-2025(2011) [PubMed] [Europe PMC] [Abstract]